Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price dropped 5.8% during mid-day trading on Thursday . The company traded as low as $1.09 and last traded at $1.13. Approximately 10,447 shares changed hands during mid-day trading, a decline of 31% from the average daily volume of 15,111 shares. The stock had previously closed at $1.20.
Humacyte Price Performance
The business’s fifty day moving average price is $1.58 and its 200-day moving average price is $1.77.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- What Makes a Stock a Good Dividend Stock?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Investing In Preferred Stock vs. Common Stock
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
